|
|
???tair.name??? >
???browser.page.title.author???
|
"blauvelt andrew"???jsp.browse.items-by-author.description???
Showing items 1-8 of 8 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 臺大學術典藏 |
2022-09-20T06:07:34Z |
Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis
|
Blauvelt, Andrew; TSEN-FANG TSAI; Langley, Richard G; Miller, Megan; Shen, Yaung-Kaung; You, Yin; Yang, Ya-Wen; Papp, Kim A; Puig, Luis |
| 臺大學術典藏 |
2022-09-20T01:07:41Z |
Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials
|
Simpson, Eric L; Papp, Kim A; Blauvelt, Andrew; CHIA-YU CHU; Hong, H Chih-Ho; Katoh, Norito; et al., |
| 臺大學術典藏 |
2022-04-14T23:27:10Z |
Efficacy and Safety of Upadacitinib in Patients with Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data from the Measure Up 1 and Measure Up 2 Randomized Clinical Trials
|
Simpson, Eric L.; Papp, Kim A.; Blauvelt, Andrew; CHIA-YU CHU; Hong, H. Chih Ho; Katoh, Norito; Calimlim, Brian M.; Thyssen, Jacob P.; Chiou, Albert S.; Bissonnette, Robert; Stein Gold, Linda F.; Wegzyn, Colleen; Hu, Xiaofei; Liu, Meng; Liu, John; Tenorio, Allan R.; Chu, Alvina D.; Guttman-Yassky, Emma |
| 臺大學術典藏 |
2021-09-08T01:25:02Z |
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
|
Guttman-Yassky, Emma; Teixeira, Henrique D.; Simpson, Eric L.; Papp, Kim A.; Pangan, Aileen L.; Blauvelt, Andrew; Thaçi, Diamant; CHIA-YU CHU; Hong, H. Chih ho; Katoh, Norito; Paller, Amy S.; Calimlim, Brian; Gu, Yihua; Hu, Xiaofei; Liu, Meng; Yang, Yang; Liu, John; Tenorio, Allan R.; Chu, Alvina D.; Irvine, Alan D. |
| 國立臺灣大學 |
2016 |
Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis
|
van de Kerkhof, Peter C. M.; Griffiths, Christopher E. M.; Reich, Kristian; Leonardi, Craig L.; Blauvelt, Andrew; Tsai, Tsen-Fang; Gong, Yankun; Huang, Jiaqing; Papavassilis, Charis; Fox, Todd; 蔡呈芳 |
| 國立臺灣大學 |
2015 |
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
|
Thaci, Diamant; Blauvelt, Andrew; Reich, Kristian; Tsai, Tsen-Fang; Vanaclocha, Francisco; Kingo, Kuelli; Ziv, Michael; Pinter, Andreas; Hugot, Sophie; You, Ruquan; Milutinovic, Marina; 蔡呈芳 |
| 國立臺灣大學 |
2015 |
Secukinumab treatment shows no evidence for reactivation of previous or latent TB infection in subjects with psoriasis: A pooled phase 3 safety analysis
|
Tsai, Tsen-Fang; Blauvelt, Andrew; Gong, Yankun; Huang, Jiaqing; Fox, Todd; 蔡呈芳 |
| 國立臺灣大學 |
2015 |
Secukinumab demonstrates an acceptable safety profile in moderate to severe plaque psoriasis: Pooled analysis of 10 phase 2/3 studies
|
Griffiths, Christopher; Reich, Kristian; Leonard, Craig; Blauvelt, Andrew; Mehta, Nehal; Tsai, Tsen-Fang; Gong, Yankun; Huang, Jiaqing; Fox, Todd; 蔡呈芳 |
Showing items 1-8 of 8 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
